8-K

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported): December 16, 2010

CHINA BOTANIC PHARMACEUTICAL INC.

(Exact name of Registrant as Specified in its Charter)

Nevada	0-24512	88-1273503
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

No. 281, Taiping Road, Taiping District

Harbin, Heilongjiang Province, 150050

(Address of Principal Executive Offices)

Registrant’s telephone number, including area code:  86-451-5762-0378

N/A

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.02. APPOINTMENT OF CERTAIN OFFICERS.

 (c) On December 16, 2010, the Company announced that Mr. David (Weiqiu) Dong, age 40, was appointed to the position of Chief Financial Officer. Since September 2006, Mr. Dong has been an Investment Manager with  Hatitac Inc., an investment manager with in excess of $5,000,000 under management, and Mr. Dong was responsible for financial planning, risk management, tax planning and company accounting services. From March 2006 to October 2008, Mr. Dong was an investment manager with HUB International, an investment manager with over $3,000,000 under management.  From September 2000 to February 2006, Mr. Dong was an Investment Manager with Freedom 55 Financial, an investment manager with over $2,000,000 under management.   From March 1998 to April 2000, Mr. Dong was a Senior Audit Manager with TianHua Accounting Firm, an accounting and tax services firm, and Mr. Dong was responsible for supervising and performing annual audits, tax and acquisition reviews of publicly listed companies and private companies.  Mr. Dong is a Certified Financial Planner and received a Bachelor Degree of Engineering from North-western Polytechnic University, Xi’an, China.

In conjunction with his employment, Mr. Dong executed an employment agreement, effective December 16, 2010, with the Company, pursuant to which he agreed to serve as the Chief Financial Officer of the Company. The agreement  provides that Mr. Dong will receive an annual base salary of RMB 600,000 per year.  In accordance with the appointment, Mr. Dong received, on December 16, 2010, an option to purchase 200,000 shares of the Company's common stock.  The option has a six (6) year term and vests 60,000 shares on the first anniversary of the date of grant and 70,000 shares on each of the second and third anniversaries of the date of grant. The exercise price of the option is $2.12, the closing price on the date of the grant (i.e., December 16, 2010). The employment agreement included provisions related to confidentiality, non-competition, non-solicitation and non-disparagement.

Additional information regarding the foregoing change is contained in the press release attached hereto as Exhibit 99.1.

Item 9.01(d). Financial Statements and Exhibits.

Exhibit No.	Description
99.1	Press Release dated December 16, 2010

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

	RENHUANG PHARMACEUTICALS, INC.
Date: December 22, 2010	By:	/s/ Shaoming Li
		Shaoming Li
		Chief Executive Officer

EXHIBIT INDEX

Exhibit
Number	Description
99.1	Press Release dated December 22, 2010

EX-99.1

Company Contact:	CCG Investor Relations:
China Botanic Pharmaceutical Inc.	Mr. Mark Collinson, Partner
Ms. Portia Tan, IR Contact	Phone: +1-310-954-1343 (Los Angeles)
Tel: 86-451-8260-2162	Email: mark.collinson@ccgir.com
Email: ir@renhuang.com	Website: www.ccgirasia.com
	Mr. Crocker Coulson, President
	ePhone: +1-646-213-1915 (New York)
	Email: crocker.coulson@ccgir.com

For Immediate Release

China Botanic Appoints David Dong as New Chief Financial Officer

HARBIN, CHINA – December 16, 2010 – China Botanic Pharmaceutical Inc. (AMEX: CBP) ("China Botanic" or the "Company"), a developer, manufacturer and distributor of botanical products, bio-pharmaceuticals and traditional Chinese medicines ("TCM"), today announced that Mr. David Dong was named the Company's new Chief Financial Officer (“CFO”) on December 14, 2010.

Mr. Dong's career spans over 10 years with key positions in finance, audit, investment advisory and tax planning. From 2000-2010, Mr. Dong worked as an investment manager with money management firms.  Most recently, he was an investment manager with Hatitac Inc., where he was responsible for funds and stock investments and was involved in financial planning, risk management, tax planning and accounting services.  He also served as an advisor to publicly and privately held institutional clients.  From 1998 to 2000, he worked as a senior audit manager with TianHua Accounting firm. He also spent five years at Tsinghua Unisplendour Co., Ltd. where he progressed from sales engineer to finance manager and was responsible for financial reporting, budgeting, general accounting, credit and collateral and procurement-related activities.  He also assisted with corporate restructuring, including relocation of Internal Audit, Tax, General Accounting, and Finance Departments to improve communication and efficiency. Mr. Dong holds a Bachelor of Engineering from North-Western Polytechnic University in China and is a Certified Financial Planner in Canada.

Mr. Shaoming Li, Chairman and Chief Executive Officer of China Botanic, stated, “Mr. Dong brings a wealth of experience and knowledge to China Botanic.  I am confident that his knowledge about capital markets will be valuable as we grow our business and expand our capabilities through targeted acquisitions. “

“I am excited by the opportunity to join a company with an attractive revenue growth and profitability track record," said Mr. Dong. "I look forward to assisting the Company in managing its financial goals and enhancing communication with shareholders to achieve long-term growth in shareholder value.”

ABOUT CHINA BOTANIC PHARMACEUTICAL INC.

China Botanic Pharmaceutical Inc. is engaged in the research, development, manufacturing, and distribution of botanical products, bio-pharmaceutical products, and traditional Chinese medicines ("TCM"), in the People's Republic of China.  All of the Company's products are produced at its three GMP-certified production facilities in Ah City, Dongfanghong and Qingyang. The Company distributes its botanical anti-depression and nerve-regulation products, biopharmaceutical products, and botanical antibiotic and OTC TCMs through its network of over 3,000 distributors and over 70 sales centers across 24 provinces in China.

Safe Harbor Statement

This press release contains certain statements that may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements are based upon management’s beliefs, assumptions and expectations of the Company’s future operations and economic performance, taking into account the information currently available to management. These statements are not statements of historical fact. Forward-looking statements involve risks and uncertainties, some of which are not currently known that may cause actual results, performance or financial condition to be materially different from the expectations of future results, performance or financial condition expressed or implied in any forward-looking statements. These forward-looking statements are based on current plans and expectations and are subject to a number of uncertainties including, but not limited to the Company’s ability to manage expansion of its operations effectively, and other factors detailed in the Company’s annual report on Form 10-K and other filings with the Securities and Exchange Commission.  The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. You are cautioned not to unduly rely on such forward-looking statements when evaluating the information presented herein.

###